摘要
目的:综合评价舒血宁注射液治疗脑梗死的有效性和安全性,为临床决策提供科学依据。方法:全面系统地检索中国知网、万方、维普、中国生物医学文献服务系统、Cochrane library和Pub Med,收集舒血宁注射液治疗脑梗死的随机对照试验,检索时间为各数据库建库至2016年4月,采用Cochrane提供的偏倚风险评价工具对纳入研究进行质量评价,并用Rev Man 5.3软件进行统计分析。结果:共纳入48个研究,累计受试者5 100例。Meta分析结果显示在西医常规治疗的基础上,联用舒血宁注射剂可明显提高临床疗效以及神经功能缺损好转程度。纳入研究中报道不良反应共26例,其中23例发生在观察组。结论:应用舒血宁注射液佐治脑梗死有较好的疗效。
Objective： To systematically evaluate the effectiveness and safety of Shuxuening Injection（ SXN） as one adjuvant therapy for treating cerebral infarction（ CI）. Methods： Randomized controlled trials（ RCTs） of CI treated by SXN were searched in CNKI,Wanfang data,VIP,Web of Science,Cochrane library,Pub Med and CBM,which from the date of databases were built to April 2016. Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5. 3 software were used to conduct the Meta-analysis of extracted data. Results： 48 RCTs including 5 100 patients were included finally. Meta-analysis results showed that the combined use of SXN and western medicine（ WM） in treatment of CI can obviously improve the total effective rate of cerebral infarction and the degree of neurologic. The included studies reported 26 adverse events,23 of which belonged to experimental groups. Conclusion： Comparing with WM,the combine use of SXN was more effective.
出处
《药物流行病学杂志》
CAS
2016年第8期492-498,共7页
Chinese Journal of Pharmacoepidemiology
基金
国家自然科学基金项目(编号:81473547)
关键词
舒血宁注射液
脑梗死
META分析
Shuxuening Injection
Cerebral infarction
Meta-analysis
作者简介
[通讯作者]吴嘉瑞，Tel：010-64287506，E—mail：exogamy@163．com
[通讯作者]张冰，Tel：010-84738630，E-mail：zhangbing6@263．net
